These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 33562791)

  • 1. Advances in Membranous Nephropathy.
    Ronco P; Plaisier E; Debiec H
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33562791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Membranous nephropathy: current understanding of various causes in light of new target antigens.
    Ronco P; Debiec H
    Curr Opin Nephrol Hypertens; 2021 May; 30(3):287-293. PubMed ID: 33480620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membranous nephropathy-diagnosis and identification of target antigens.
    Sethi S; Fervenza FC
    Nephrol Dial Transplant; 2024 Mar; 39(4):600-606. PubMed ID: 37863839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Podocyte Antigen Staining to Identify Distinct Phenotypes and Outcomes in Membranous Nephropathy: A Retrospective Multicenter Cohort Study.
    Hanset N; Aydin S; Demoulin N; Cosyns JP; Castanares-Zapatero D; Crott R; Cambier JF; Pochet JM; Gillerot G; Reginster F; Houssiau F; Debiec H; Ronco P; Jadoul M; Morelle J;
    Am J Kidney Dis; 2020 Nov; 76(5):624-635. PubMed ID: 32668319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Membranous Nephropathy.
    Couser WG
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of Anti-Semaphorin 3B-Mediated Membranous Nephropathy after Kidney Transplantation.
    Fila M; Debiec H; Perrochia H; Djouadi N; Verpont MC; Buob D; Ronco P
    J Am Soc Nephrol; 2022 Mar; 33(3):503-509. PubMed ID: 35017170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membranous Nephropathy: Core Curriculum 2021.
    Alsharhan L; Beck LH
    Am J Kidney Dis; 2021 Mar; 77(3):440-453. PubMed ID: 33487481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal.
    Rojas-Rivera JE; Carriazo S; Ortiz A
    Clin Kidney J; 2019 Oct; 12(5):629-638. PubMed ID: 31583088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study.
    Rojas-Rivera J; Fernández-Juárez G; Ortiz A; Hofstra J; Gesualdo L; Tesar V; Wetzels J; Segarra A; Egido J; Praga M
    Clin Kidney J; 2015 Oct; 8(5):503-10. PubMed ID: 26413273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.
    Sethi S; Debiec H; Madden B; Vivarelli M; Charlesworth MC; Ravindran A; Gross L; Ulinski T; Buob D; Tran CL; Emma F; Diomedi-Camassei F; Fervenza FC; Ronco P
    Kidney Int; 2020 Nov; 98(5):1253-1264. PubMed ID: 32534052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial.
    Scolari F; Dallera N; Gesualdo L; Santoro D; Pani A; Santostefano M; Feriozzi S; Mani LY; Boscutti G; Messa P; Magistroni R; Quaglia M; Ponticelli C; Ravani P
    BMJ Open; 2019 Dec; 9(12):e029232. PubMed ID: 31806605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
    Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Target Antigen-Based Approach to the Classification of Membranous Nephropathy.
    Bobart SA; Tehranian S; Sethi S; Alexander MP; Nasr SH; Moura Marta C; Vrana JA; Said S; Giesen CD; Lieske JC; Fervenza FC; De Vriese AS
    Mayo Clin Proc; 2021 Mar; 96(3):577-591. PubMed ID: 33673911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of membranous nephropathy: Perspectives on current and future therapies.
    Shah M; DeLaat A; Cavanaugh C
    Front Nephrol; 2023; 3():1110355. PubMed ID: 37675368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.
    Sethi S; Debiec H; Madden B; Charlesworth MC; Morelle J; Gross L; Ravindran A; Buob D; Jadoul M; Fervenza FC; Ronco P
    Kidney Int; 2020 Jan; 97(1):163-174. PubMed ID: 31901340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.
    Scolari F; Delbarba E; Santoro D; Gesualdo L; Pani A; Dallera N; Mani LY; Santostefano M; Feriozzi S; Quaglia M; Boscutti G; Ferrantelli A; Marcantoni C; Passerini P; Magistroni R; Alberici F; Ghiggeri GM; Ponticelli C; Ravani P;
    J Am Soc Nephrol; 2021 Apr; 32(4):972-982. PubMed ID: 33649098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
    Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
    J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of Membranous Nephropathy in Asia.
    Xu J; Hu X; Xie J; Chen N
    Kidney Dis (Basel); 2015 Sep; 1(2):119-25. PubMed ID: 27536672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Clinicopathologic Spectrum of Membranous Nephropathy with Lupus-Like Features.
    Choung HYG; Moore C; Le TH; Guirguis P; McKeown JM; Jean-Gilles J; Goldman B
    Nephron; 2023; 147(7):424-433. PubMed ID: 36746127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Membranous Nephropathy With Enhanced Staining of Exostosin 1/Exostosin 2 in the Glomeruli: A Report of 2 Cases.
    Iwakura T; Ema C; Sato T; Isobe S; Fujikura T; Ohashi N; Kato A; Yasuda H
    Kidney Med; 2021; 3(4):669-673. PubMed ID: 34401734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.